Arrowhead Pharmaceuticals has submitted an NDA to the FDA for plozasiran, targeting familial chylomicronemia syndrome (FCS), a rare genetic disease with no approved treatments.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.